Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
83 hedge funds and large institutions have $155M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
81% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 16
26% more funds holding
Funds holding: 66 → 83 (+17)
14% more capital invested
Capital invested by funds: $135M → $155M (+$19.6M)
81% less call options, than puts
Call options by funds: $976K | Put options by funds: $5.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
+$2.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.81M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.67M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.36M |
| 5 |
Morgan Stanley
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.46M |
| 3 |
RA
Rational Advisors
Huntington,
New York
|
-$286K |
| 4 |
Citigroup
New York
|
-$219K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$192K |
OSIR Hedge Fund Activity: Q1 2015 in Review
83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2015, worth a combined $155M — up 14% from $135M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new OSIR positions and 4 closed out — a net gain of 18 holders — while 29 added to existing stakes and 16 trimmed.
The largest buyer was Venator Capital Management, opening a new position worth an estimated $2.94M. The largest seller was Consonance Capital Management, cutting an estimated $8M.
- 83 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2015, up from 66 in Q4 2014.
- Funds reported $155M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2015, up 14% quarter-over-quarter.
- 22 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2015 and 4 closed out, a net change of +18 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2015 was Venator Capital Management, an estimated $2.94M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2015 was Consonance Capital Management, an estimated $8M sold.
Based on aggregated 13F filings for Q1 2015.